Thrive Capital
US growth-equity VC; led Isomorphic Labs $2.1bn Series B in May 2026.
Last refreshed: 13 May 2026 · Appears in 1 active topic
Why did Thrive Capital back a UK AI lab over Silicon Valley rivals?
Timeline for Thrive Capital
Sovereign AI unit backs Alphabet-owned lab
UK Startups and Innovation- Who founded Thrive Capital and what do they invest in?
- Thrive Capital was founded by Joshua Kushner in 2009. It manages around $25bn in assets and focuses on late-stage technology and life-sciences companies, including frontier AI labs.Source: Wikipedia
- Why did Thrive Capital lead the Isomorphic Labs funding round?
- Thrive Capital led Isomorphic Labs' $2.1bn Series B in May 2026, the largest venture round in UK life-sciences history, backing the Alphabet-owned AI drug-discovery lab to accelerate its small-molecule pipeline.Source: event
- How much does Thrive Capital manage?
- Thrive Capital manages approximately $25bn in assets under management as of 2026.Source: Crunchbase
- What other technology companies has Thrive Capital invested in?
- Thrive Capital has backed Instagram, Stripe, GitHub, Spotify, and several frontier AI labs, typically at growth stages.Source: Wikipedia
Background
Thrive Capital is a New York-based growth-equity firm founded by Joshua Kushner in 2009. It manages approximately $25bn in assets and focuses on late-stage technology and life-sciences companies. The firm has backed some of the most capitalised private companies of the past decade, including Instagram, Spotify, GitHub, and Stripe, typically writing large cheques at Series B and beyond. Its investment thesis centres on businesses where software creates durable structural advantages, which has brought it increasingly into contact with frontier AI labs.
In May 2026 Thrive Capital led Isomorphic Labs' $2.1bn Series B, the largest single venture round ever raised by a UK life-sciences company. Isomorphic, the Alphabet-owned drug-discovery spinout of DeepMind, used the raise to accelerate its AI-driven small-molecule pipeline and expand its pharmaceutical partnerships. Thrive's involvement signals that the largest US growth-equity funds are now treating sovereign AI labs as a credible alternative to US-headquartered frontier models for capital deployment.